HK Stock Market Move | DIAGENS-B(02526) has risen by over 7%, it is expected that AI AutoVision will become the first intelligent chromosomal karyotype assisted diagnosis software in China.

DIAGENS-B (02526) rose more than 7%, as of the time of publication, it has increased by 6.02%, reaching 299.2 Hong Kong dollars, with a turnover of 27.4316 million Hong Kong dollars. Public information shows that DeShi focuses on underlying technological innovation in the field of AI medical imaging, and its independently developed iMedImage medical imaging platform model supports 19 imaging modalities and can empower over 90% of clinical imaging scenarios. Based on massive pre-training data, iMedImage can quickly train disease-specific models for imaging diagnosis, achieving an industry breakthrough of "few samples, low computational power, fast training." Currently, AI AutoVision has been designated as a Class III Innovative Medical Management Instrument by the National Medical Products Administration. DeShi disclosed in its prospectus that after communicating with the National Medical Products Administration Medical Device Technology Evaluation Center in December 2025, it was confirmed that the regulatory agency had no objections to the registration approval of AI AutoVision, with only related procedures and administrative matters awaiting completion. If finally approved for listing, it will become the first domestic intelligent software for chromosomal karyotyping auxiliary diagnosis to be approved for listing.